ClinicalTrials.gg
CompletedNCT00902486Updated Sep 4, 2018Results posted

INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs

A Phase 2 interventional study of INCB028050 and INCB028050 in Rheumatoid Arthritis, sponsored by Incyte Corporation. Completed at 49 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-04.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
127
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing baricitinib in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, 1 of them phase 3. baricitinib · Arthritis, Rheumatoid.

Enrollment
15th of 23
127 · median 290
Started
2009
the only one that year
Phase 2
3 of 23
none open now
Registered
1st of 23
by date
Lead sponsor
1 of 23
Incyte Corporation

Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, this one is the 15th largest by enrollment, is the only one that started in 2009, is one of 3 in phase 2, and was the 1st registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 23 studies testing baricitinib in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About baricitinib

baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing baricitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This was a randomized, double blind, placebo controlled, dose ranging, parallel group study. Participants who had active rheumatoid arthritis (RA) who had inadequate response to any disease modifying anti-rheumatic drug (DMARD) therapy including biologics were enrolled. Screening evaluations were performed within approximately 28 days of randomization. The duration of the study was 6 months with the primary endpoint assessed at 3 months. Eligible participants were randomly assigned to one of three doses (4, 7 or 10 mg QD) of INCB028050 (Baricitinib) or placebo.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have rheumatoid arthritis which has been inadequately controlled with at least one DMARD
  • For subjects receiving antimalarials, they must be treated with antimalarials for at least 6 months and receiving a stable daily dose
  • For subjects receiving sulfasalazine, they must be treated with Sulfasalazine (SSZ) for at least 6 months and receiving a stable daily dose of no more than 3 grams per day
  • For subjects on methotrexate, they must be treated with methotrexate for at least 6 months, and receiving a stable weekly dose of methotrexate between 7.5 and 25 mg
  • For subjects on leflunomide, they must be treated with leflunomide for at least 6 months, and receiving a stable dose of leflunomide between 10 to 20 mg
  • For subjects receiving , they must be on a dose not to exceed 10 mg of prednisone daily
  • Active rheumatoid arthritis at the time of screening defined by the following: 6 or more joints tender or painful on motion and 4 or more swollen joints and at least one of the following two: Erythrocyte sedimentation rate (ESR) greater than or equal to 28 mm/hr or C-reactive protein (CRP) greater than or equal to 7 mg/liter
  • Have evidence of lack of risk for tuberculosis

Exclusion criteria

Exclusion Criteria:

  • Current or recent viral, bacterial, fungal, parasitic or mycobacterial infection requiring systemic therapy
  • History of infected joint prosthesis
  • Subjects who have a current or recent history of severe, progressive, uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological or cerebral disease
  • Subjects who have received treatment with the following drugs or drug classes within the specified timeframe: prior treatment with rituximab within 12 months, prior treatment with an oral Janus kinase (JAK) inhibitor, DMARDs or other anti-rheumatic therapies not specified and allowed according to protocol, treatment with any medication within 12 weeks or 5 half-lives (whichever is longer), and treatment with a biologic agent within 12 weeks prior to the first dose of study medication
  • Subjects with a past history of neutropenia, thrombocytopenia or anemia requiring transfusion other than at the time of trauma or surgery, and subjects that meet protocol specified laboratory measures
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
127 participants (actual)

Study arms

  • Experimental
    INCB028050 4 mg QD

    INCB028050 4mg Once daily (QD)

    Drug: INCB028050

  • Experimental
    INCB028050 7 mg QD

    INCB028050 7mg QD

    Drug: INCB028050

  • Experimental
    INCB028050 10 mg QD

    INCB028050 10mg QD

    Drug: INCB028050

  • Placebo comparator
    Placebo

    Placebo group may 'cross-over' following 3 months of treatment to receive either active arm #2 (7mg QD) or active arm #3 (10mg QD) of INCB028050 capsules.

    Drug: Placebo

Interventions

  • 4 mg capsules QD

    Also known as: Baricitinib

  • 7 mg capsules QD

    Also known as: Baricitinib

  • 10 mg capsule QD

    Also known as: Baricitinib

  • DrugPlacebo

    Placebo matching INCB028050 QD

06

What researchers measure

Primary outcomes

  1. The Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Improvement

    The ACR 20 is defined as ≥ 20% improvement in tender joint count plus ≥ 20% improvement in swollen joint count plus ≥ 20% improvement in 3 of the following 5 criteria: participants' assessment of pain, participants' global assessment of disease activity (PGA), Physician's global assessment of disease activity (PHGA), participants' self-assessed disability Health Assessment Questionnaire (HAQ), and Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), whichever shows the greatest change.

    Time frame: Week 12

  2. Participants With at Least 1 Adverse Event From Baseline Through Week 12

    Time frame: From Baseline through week 12

Secondary outcomes

  1. Participants With at Least 1 Adverse Event From Week 12 to Week 24

    Time frame: Week 12 to Week 24

  2. The Percentage of Participants Who Were Assigned to Active Treatment at Baseline Achieving ACR 20 Improvement at Week 24

    The ACR 20 is defined as ≥ 20% improvement in tender joint count plus ≥ 20% improvement in swollen joint count plus ≥ 20% improvement in 3 of the following 5 criteria: participants' assessment of pain, participants' global assessment of disease activity (PGA), Physician's global assessment of disease activity (PHGA), participants' self-assessed disability Health Assessment Questionnaire (HAQ), and Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), whichever shows the greatest change.

    Time frame: From Baseline to Week 24

  3. The Percentage of Participants Achieving American College of Rheumatology (ACR) 50 Improvement at Week 12 and Week 24

    The ACR 50 is defined as ≥ 50% improvement in tender joint count plus ≥ 50% improvement in swollen joint count plus ≥50% improvement in 3 of the following 5 criteria: participants' assessment of pain, PGA, PHGA, participants' self-assessed disability HAQ, and ESR or CRP, whichever shows the greatest change.

    Time frame: Week 12 and Week 24

  4. The Percentage of Participants Achieving American College of Rheumatology (ACR) 70 Improvement at Week 12 and Week 24

    The ACR 70 is defined as ≥ 70% improvement in tender joint count plus ≥ 70% improvement in swollen joint count plus ≥ 70% improvement in 3 of the following 5 criteria: participants' assessment of pain, PGA, PHGA, participants' self-assessed disability HAQ, and ESR or CRP, whichever shows the greatest change.

    Time frame: Week 12 and Week 24

  5. The Percentage of Participants Achieving American College of Rheumatology (ACR) 90 Improvement at Week 12 and Week 24

    The ACR 90 is defined greater than or equal to (\>=) 90 percent (%) improvement in painful and tender joint count; \>= 90% improvement in swollen joint count; and \>= 90% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP) at each visit.

    Time frame: Week 12 and Week 24

  6. Change in Disease Activity Score 28 (DAS28) CRP Score From Baseline at Week 12 and Week 24

    Calculation of the disease activity score 28 (DAS 28) score was based on the tender joint count, plus swollen joint count, plus PGA, plus C-reactive protein (CRP). A higher score indicated more disease activity. The mean change from baseline (which represent decreases in the DAS 28 CRP scores) are shown as positive numbers in these analyses. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (\>5.1=high disease activity; \<3.2=low disease activity; \<2.6=remission).

    Time frame: Baseline, Week 12 and Week 24

  7. Change in Disease Activity Score 28 (DAS28) ESR Score From Baseline at Week 12 and Week 24

    Calculation of the disease activity score 28 (DAS 28) score was based on the tender joint count, plus swollen joint count, plus PGA, plus Erythrocyte sedimentation rate (ESR). The DAS28-ESR is expressed as units on a scale with the minimum score=0 (best) to maximum score=10 (worst). Remission was defined as DAS28-ESR \<2.6. The mean change from baseline (which represent decreases in the DAS 28 ESR scores) are shown as positive numbers in these analyses.

    Time frame: Baseline, Week 12 and Week 24

  8. Percentage of Participants Achieving Low Disease Activity by DAS28 (ESR)≤3.2

    Participants who achieved low disease activity based on the DAS 28 ESR (score ≤3.2). Participants who achieved low disease activity were classified as responders in this analysis.

    Time frame: Week 12 and Week 24

  9. Percentage of Participants Achieving Remission by DAS28 (ESR) ≤2.6

    Participants who achieved inactive disease based on the DAS 28 ESR (score ≤2.6). Participants who achieved low disease activity were classified as responders in this analysis.

    Time frame: Week 12 and Week 24

  10. Percentage of Participants Achieving Remission by DAS28 (CRP) ≤2.6

    Participants who achieved inactive disease based on DAS 28 CRP (score ≤2.6). Participants who achieved low disease activity were classified as responders in this analysis.

    Time frame: Week 12 and Week 24

  11. Change in ACR Assessment Tender Joint Count (TJC) From Baseline to Week 12 and Week 24

    The 28 joints to be assessed for tenderness and swelling were shoulder, elbow, wrist, metacarpophalangeal (MCP) joints 1-5, proximal interphalangeal (PIP) joints 1-5, and knee on both sides of the body. The sum of tender joints ranged from 0 to 28 with 0 as best possible health status and 28 as worst health status.

    Time frame: Baseline, Week 12 and Week 24

  12. Change in ACR Assessment Swollen Joint Count (SJC) From Baseline to Week 12 and Week 24

    The 28 joints to be assessed for tenderness and swelling were shoulder, elbow, wrist, metacarpophalangeal (MCP) joints 1-5, proximal interphalangeal (PIP) joints 1-5, and knee on both sides of the body. The sum of tender joints ranged from 0 to 28 with 0 as best possible health status and 28 as worst health status.

    Time frame: Baseline, Week 12 and Week 24

  13. Change in Participants' Assessment of Pain From Baseline at Week 12 and Week 24

    Participants were to assess their current level of pain on a 100 mm horizontal Visual Analog Scale (VAS). The left-hand extreme of the line (0 mm) was described as "no pain" and the right-hand (100 mm) as "most imaginable pain".

    Time frame: Baseline, Week 12 and Week 24

  14. Change in Participants' Global Assessment of Disease Activity From Baseline at Week 12 and Week 24

    Participants were to assess the disease (RA) activity on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no arthritis activity" (symptom-free and no arthritis symptoms) and the right hand extreme (100 mm) as "extremely active arthritis" (maximum arthritis disease activity). A decreasing mean score, therefore, indicates improvement.

    Time frame: Baseline, Week 12 and Week 24

  15. Change in Physician's Global Assessment of Disease Activity (PGA) From Baseline at Week 12 and Week 24

    Physicians were to assess the disease (RA) activity on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no arthritis activity" (symptom-free and no arthritis symptoms) and the right hand extreme (100 mm) as "extremely active arthritis" (maximum arthritis disease activity). A decreasing mean score, therefore, indicates improvement.

    Time frame: Baseline, Week 12 and Week 24

  16. Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Baseline at Week 12 and Week 24

    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

    Time frame: Baseline, Week 12 and Week 24

  17. Change in Erythrocyte Sedimentation Rate (ESR) From Baseline at Week 12 and Week 24

    ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 millimeter/hour (mm/hr). A higher rate is consistent with inflammation.

    Time frame: Baseline, Week 12 and Week 24

  18. Change in C-reactive Protein (CRP) From Baseline at Week 12 and Week 24

    The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.

    Time frame: Baseline, Week 12 and Week 24

  19. Change in Duration of Morning Stiffness From Baseline at Week 12 and Week 24

    Duration of morning stiffness was defined as the time elapsed when participant woke up in the morning and was able to resume normal activities without stiffness in minutes (If none was present = 0; If morning stiffness was continuing at the time of assessment or was unusual compared to the recent past, average of duration of stiffness over the past 3 days was reported; If stiffness persisted the entire day, 1440 minutes was recorded).

    Time frame: Baseline, Week 12 and Week 24

  20. Percentage of Participants Achieving Good European League Against Rheumatism (EULAR) Response (DAS28 ESR) at Week 12

    EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2.

    Time frame: Week 12

  21. Percentage of Participants Achieving Good EULAR Response (DAS28ESR) at Week 24

    EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2.

    Time frame: Week 24

  22. Percentage of Participants Achieving Good EULAR Response (DAS28CRP) at Week 12

    EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 2.6.

    Time frame: Week 12

  23. Percentage of Participants Achieving Good EULAR Response (DAS28CRP) at Week 24

    EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 2.6.

    Time frame: Week 24

  24. Change in SF-36 Mental Component Summary From Baseline at Week 12 and Week 24

    The Health Assessment Questionnaire Short Form 36 (SF-36) determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Scales 5-8 primarily contribute to the mental component summary score (PCS) of the SF-36. Scores on each scale are summed and averaged (range = 0 "worst"-100 "best").

    Time frame: Baseline, Week 12 and Week 24

  25. Change in SF-36 Physical Component Summary From Baseline at Week 12 and Week 24

    The Health Assessment Questionnaire Short Form 36 (SF-36) determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Scales 1-4 primarily contribute to the physical component summary score (PCS) of the SF-36. Scores on each scale are summed and averaged (range = 0 "worst"-100 "best").

    Time frame: Baseline, Week 12 and Week 24

  26. Percent of Participants Achieving a Minimum Clinically Important Difference (MCID) in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 and Week 24

    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. The MCID score for HAQ-DI is -0.22.

    Time frame: Week 12 and Week 24

  27. Percent of Participants Achieving a MCID in the Pain Score (Participant's Assessment of Pain) at Week 12 and Week 24

    Participants were to assess their current level of pain on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no pain" and the right-hand (100 mm) as "most imaginable pain". MCID for the pain score is a decrease of at least 10 mm on a 100 mm scale.

    Time frame: Week 12 and Week 24

  28. Percent of Participants Achieving a MCID in the SF-36 Physical Components and Mental Components at Week 12 and Week 24

    The Health Assessment Questionnaire Short Form 36 (SF-36) determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Scales 5-8 primarily contribute to the mental component summary score (PCS) of the SF-36. Scores on each scale are summed and averaged (range = 0 "worst"-100 "best").

    Time frame: Week 12 and Week 24

07

Results

Posted Sep 4, 2018

Participant flow

The study population included participants diagnosed with RA who had failed to respond adequately to any DMARD therapy, including biologics.

Treatment Period (Weeks 0 Through 12)
Participant flow — Treatment Period (Weeks 0 Through 12)
MilestonePlaceboPlacebo Crossing Over to 7 mg INCB028050 QDPlacebo Crossing Over to 10 mg INCB028050 QDINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Started3100323232
Safety evaluable participants3100313231
Modified intent-to-treat participants3100313230
Completed2900293027
Not completed200325
Withdrew: Adverse event100112
Withdrew: Consent withdrawn100002
Withdrew: Protocol deviation000011
Withdrew: Lost to follow-up000100
Withdrew: Corrected qt (qtc) exclusion criteria000100
Extension Period (Weeks 12 Through 24)
Participant flow — Extension Period (Weeks 12 Through 24)
MilestonePlaceboPlacebo Crossing Over to 7 mg INCB028050 QDPlacebo Crossing Over to 10 mg INCB028050 QDINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Started01415293027
Completed01413272924
Not completed002213
Withdrew: Adverse event000012
Withdrew: Consent withdrawn001100
Withdrew: Protocol deviation000001
Withdrew: Disease progression000100
Withdrew: Lost to follow-up001000
Follow-up (After Week 24)
Participant flow — Follow-up (After Week 24)
MilestonePlaceboPlacebo Crossing Over to 7 mg INCB028050 QDPlacebo Crossing Over to 10 mg INCB028050 QDINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Started01413272924
Safety evaluable participants01415293027
Completed01413262924
Not completed000100
Withdrew: Lost to follow-up000100

Outcome measures

PrimaryThe Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Improvement

The ACR 20 is defined as ≥ 20% improvement in tender joint count plus ≥ 20% improvement in swollen joint count plus ≥ 20% improvement in 3 of the following 5 criteria: participants' assessment of pain, participants' global assessment of disease activity (PGA), Physician's global assessment of disease activity (PHGA), participants' self-assessed disability Health Assessment Questionnaire (HAQ), and Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), whichever shows the greatest change.

Time frame:
Week 12
Reported as:
Count of participants · Participants
The Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Improvement
ParticipantsPlaceboINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
The Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Improvement10161916
Statistical analysis
  • Placebo vs INCB028050 4 mg QD vs INCB028050 7 mg QD vs INCB028050 10 mg QD · Cochran-Armitage trend test · p = 0.0619 · Odds ratio (or): 2.17 · 95% CI 0.77 to 6.15LOGISTIC regression model for odds ratio estimates : LOGIT(Response 0/1) = Treatment + Biologics
  • Placebo vs INCB028050 4 mg QD · Fisher Exact · p = 0.1978
  • Placebo vs INCB028050 7 mg QD · Fisher Exact · p = 0.0437
  • Placebo vs INCB028050 10 mg QD · Fisher Exact · p = 0.1236
PrimaryParticipants With at Least 1 Adverse Event From Baseline Through Week 12
Time frame:
From Baseline through week 12
Reported as:
Count of participants · Participants
Participants With at Least 1 Adverse Event From Baseline Through Week 12
ParticipantsPlaceboINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Participants With at Least 1 Adverse Event From Baseline Through Week 1219152023
SecondaryParticipants With at Least 1 Adverse Event From Week 12 to Week 24
Time frame:
Week 12 to Week 24
Reported as:
Count of participants · Participants
Participants With at Least 1 Adverse Event From Week 12 to Week 24
ParticipantsPlacebo Crossing Over to 7 mg INCB028050 QDPlacebo Crossing Over to 10 mg INCB028050 QDINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Participants With at Least 1 Adverse Event From Week 12 to Week 2465121616
SecondaryThe Percentage of Participants Who Were Assigned to Active Treatment at Baseline Achieving ACR 20 Improvement at Week 24

The ACR 20 is defined as ≥ 20% improvement in tender joint count plus ≥ 20% improvement in swollen joint count plus ≥ 20% improvement in 3 of the following 5 criteria: participants' assessment of pain, participants' global assessment of disease activity (PGA), Physician's global assessment of disease activity (PHGA), participants' self-assessed disability Health Assessment Questionnaire (HAQ), and Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), whichever shows the greatest change.

Time frame:
From Baseline to Week 24
Reported as:
Count of participants · Participants
The Percentage of Participants Who Were Assigned to Active Treatment at Baseline Achieving ACR 20 Improvement at Week 24
ParticipantsINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
The Percentage of Participants Who Were Assigned to Active Treatment at Baseline Achieving ACR 20 Improvement at Week 24182018
SecondaryThe Percentage of Participants Achieving American College of Rheumatology (ACR) 50 Improvement at Week 12 and Week 24

The ACR 50 is defined as ≥ 50% improvement in tender joint count plus ≥ 50% improvement in swollen joint count plus ≥50% improvement in 3 of the following 5 criteria: participants' assessment of pain, PGA, PHGA, participants' self-assessed disability HAQ, and ESR or CRP, whichever shows the greatest change.

Time frame:
Week 12 and Week 24
Reported as:
Number · percentage of participants
The Percentage of Participants Achieving American College of Rheumatology (ACR) 50 Improvement at Week 12 and Week 24
percentage of participantsPlaceboINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Week 1213.035.031.030.0
Week 24NA33.037.044.0
SecondaryThe Percentage of Participants Achieving American College of Rheumatology (ACR) 70 Improvement at Week 12 and Week 24

The ACR 70 is defined as ≥ 70% improvement in tender joint count plus ≥ 70% improvement in swollen joint count plus ≥ 70% improvement in 3 of the following 5 criteria: participants' assessment of pain, PGA, PHGA, participants' self-assessed disability HAQ, and ESR or CRP, whichever shows the greatest change.

Time frame:
Week 12 and Week 24
Reported as:
Number · percentage of participants
The Percentage of Participants Achieving American College of Rheumatology (ACR) 70 Improvement at Week 12 and Week 24
percentage of participantsPlaceboINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Week 123.016.09.010.0
Week 24NA26.030.028.0
SecondaryThe Percentage of Participants Achieving American College of Rheumatology (ACR) 90 Improvement at Week 12 and Week 24

The ACR 90 is defined greater than or equal to (\>=) 90 percent (%) improvement in painful and tender joint count; \>= 90% improvement in swollen joint count; and \>= 90% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP) at each visit.

Time frame:
Week 12 and Week 24
Reported as:
Number · percentage of participants
The Percentage of Participants Achieving American College of Rheumatology (ACR) 90 Improvement at Week 12 and Week 24
percentage of participantsPlaceboINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Week 120.03.00.03.0
Week 24NA11.010.012.0
SecondaryChange in Disease Activity Score 28 (DAS28) CRP Score From Baseline at Week 12 and Week 24

Calculation of the disease activity score 28 (DAS 28) score was based on the tender joint count, plus swollen joint count, plus PGA, plus C-reactive protein (CRP). A higher score indicated more disease activity. The mean change from baseline (which represent decreases in the DAS 28 CRP scores) are shown as positive numbers in these analyses. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (\>5.1=high disease activity; \<3.2=low disease activity; \<2.6=remission).

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · Units on a scale
Change in Disease Activity Score 28 (DAS28) CRP Score From Baseline at Week 12 and Week 24
Units on a scalePlaceboINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Baseline5.71 ± 0.8755.64 ± 1.0985.76 ± 0.9255.64 ± 0.774
Change from baseline at Week 12-1.01 ± 1.245-1.87 ± 1.231-1.83 ± 1.534-1.84 ± 1.143
Change from baseline at Week 24NA ± NA-2.13 ± 1.355-2.23 ± 1.548-2.75 ± 1.234
SecondaryChange in Disease Activity Score 28 (DAS28) ESR Score From Baseline at Week 12 and Week 24

Calculation of the disease activity score 28 (DAS 28) score was based on the tender joint count, plus swollen joint count, plus PGA, plus Erythrocyte sedimentation rate (ESR). The DAS28-ESR is expressed as units on a scale with the minimum score=0 (best) to maximum score=10 (worst). Remission was defined as DAS28-ESR \<2.6. The mean change from baseline (which represent decreases in the DAS 28 ESR scores) are shown as positive numbers in these analyses.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · Units on a scale
Change in Disease Activity Score 28 (DAS28) ESR Score From Baseline at Week 12 and Week 24
Units on a scalePlaceboINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Baseline6.56 ± 0.8406.41 ± 1.0246.35 ± 0.9686.37 ± 0.851
Change from baseline at Week 12-1.25 ± 1.489-1.87 ± 1.342-1.97 ± 1.613-1.90 ± 1.481
Change from baseline at Week 24NA ± NA-2.17 ± 1.524-2.29 ± 1.455-2.79 ± 1.394
SecondaryPercentage of Participants Achieving Low Disease Activity by DAS28 (ESR)≤3.2

Participants who achieved low disease activity based on the DAS 28 ESR (score ≤3.2). Participants who achieved low disease activity were classified as responders in this analysis.

Time frame:
Week 12 and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Low Disease Activity by DAS28 (ESR)≤3.2
percentage of participantsPlaceboINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Week 1219.023.031.013.0
Week 24NA48.053.065.0
SecondaryPercentage of Participants Achieving Remission by DAS28 (ESR) ≤2.6

Participants who achieved inactive disease based on the DAS 28 ESR (score ≤2.6). Participants who achieved low disease activity were classified as responders in this analysis.

Time frame:
Week 12 and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Remission by DAS28 (ESR) ≤2.6
percentage of participantsPlacebo to INCB028050 7 mg QDPlacebo to INCB028050 10 mg QDINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Week 126.718.816.019.07.0
Week 2421.423.122.027.026.0
SecondaryPercentage of Participants Achieving Remission by DAS28 (CRP) ≤2.6

Participants who achieved inactive disease based on DAS 28 CRP (score ≤2.6). Participants who achieved low disease activity were classified as responders in this analysis.

Time frame:
Week 12 and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Remission by DAS28 (CRP) ≤2.6
percentage of participantsINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Week 1223.025.017.0
Week 2430.040.048.0
SecondaryChange in ACR Assessment Tender Joint Count (TJC) From Baseline to Week 12 and Week 24

The 28 joints to be assessed for tenderness and swelling were shoulder, elbow, wrist, metacarpophalangeal (MCP) joints 1-5, proximal interphalangeal (PIP) joints 1-5, and knee on both sides of the body. The sum of tender joints ranged from 0 to 28 with 0 as best possible health status and 28 as worst health status.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · Tender joints
Change in ACR Assessment Tender Joint Count (TJC) From Baseline to Week 12 and Week 24
Tender jointsPlaceboINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Baseline15.9 ± 6.6714.4 ± 6.5814.7 ± 6.7015.9 ± 6.37
Change from baseline at Week 12-5.3 ± 6.40-7.4 ± 6.21-6.4 ± 7.98-8.8 ± 8.86
Change from baseline at Week 24NA ± NA-8.3 ± 6.17-8.7 ± 7.42-12.0 ± 8.19
SecondaryChange in ACR Assessment Swollen Joint Count (SJC) From Baseline to Week 12 and Week 24

The 28 joints to be assessed for tenderness and swelling were shoulder, elbow, wrist, metacarpophalangeal (MCP) joints 1-5, proximal interphalangeal (PIP) joints 1-5, and knee on both sides of the body. The sum of tender joints ranged from 0 to 28 with 0 as best possible health status and 28 as worst health status.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · Swollen joints
Change in ACR Assessment Swollen Joint Count (SJC) From Baseline to Week 12 and Week 24
Swollen jointsPlaceboINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Baseline11.0 ± 5.2812.0 ± 5.4810.6 ± 4.5712.9 ± 5.12
Change from baseline at Week 12-3.7 ± 4.02-6.1 ± 4.43-5.4 ± 5.85-7.2 ± 5.57
Change from baseline at Week 24NA ± NA-7.3 ± 5.14-6.2 ± 5.04-9.1 ± 5.10
SecondaryChange in Participants' Assessment of Pain From Baseline at Week 12 and Week 24

Participants were to assess their current level of pain on a 100 mm horizontal Visual Analog Scale (VAS). The left-hand extreme of the line (0 mm) was described as "no pain" and the right-hand (100 mm) as "most imaginable pain".

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · millimeter (mm)
Change in Participants' Assessment of Pain From Baseline at Week 12 and Week 24
millimeter (mm)PlaceboINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Baseline62.37 ± 21.07957.08 ± 24.71663.25 ± 18.65657.00 ± 22.995
Change from baseline at Week 12-6.24 ± 22.065-21.98 ± 26.275-22.19 ± 25.631-22.97 ± 37.691
Change from baseline at Week 24NA ± NA-22.13 ± 27.294-27.62 ± 25.015-30.39 ± 30.847
SecondaryChange in Participants' Global Assessment of Disease Activity From Baseline at Week 12 and Week 24

Participants were to assess the disease (RA) activity on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no arthritis activity" (symptom-free and no arthritis symptoms) and the right hand extreme (100 mm) as "extremely active arthritis" (maximum arthritis disease activity). A decreasing mean score, therefore, indicates improvement.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · millimeter (mm)
Change in Participants' Global Assessment of Disease Activity From Baseline at Week 12 and Week 24
millimeter (mm)PlaceboINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Baseline66.19 ± 20.52259.02 ± 26.31469.69 ± 18.89362.25 ± 21.346
Change from baseline at Week 12-8.61 ± 22.569-22.06 ± 27.366-27.41 ± 21.990-25.48 ± 32.879
Change from baseline at Week 24NA ± NA-24.02 ± 26.921-31.53 ± 23.891-34.08 ± 27.518
SecondaryChange in Physician's Global Assessment of Disease Activity (PGA) From Baseline at Week 12 and Week 24

Physicians were to assess the disease (RA) activity on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no arthritis activity" (symptom-free and no arthritis symptoms) and the right hand extreme (100 mm) as "extremely active arthritis" (maximum arthritis disease activity). A decreasing mean score, therefore, indicates improvement.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · millimeter (mm)
Change in Physician's Global Assessment of Disease Activity (PGA) From Baseline at Week 12 and Week 24
millimeter (mm)PlaceboINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Baseline63.45 ± 16.90361.94 ± 19.16259.80 ± 17.18559.32 ± 16.890
Change from baseline at Week 12-20.23 ± 19.824-33.87 ± 24.283-29.95 ± 25.741-30.88 ± 19.334
Change from baseline at Week 24NA ± NA-38.78 ± 22.527-36.94 ± 21.235-38.94 ± 21.776
SecondaryChange in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Baseline at Week 12 and Week 24

HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · Score on a scale
Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Baseline at Week 12 and Week 24
Score on a scalePlaceboINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Baseline1.61 ± 0.4941.50 ± 0.6011.67 ± 0.4741.50 ± 0.590
Change from baseline at Week 12 (n=31, 31, 30, 30)-0.20 ± 0.367-0.38 ± 0.568-0.48 ± 0.613-0.33 ± 0.539
Change from baseline at Week 24NA ± NA-0.56 ± 0.673-0.63 ± 0.563-0.39 ± 0.469
SecondaryChange in Erythrocyte Sedimentation Rate (ESR) From Baseline at Week 12 and Week 24

ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 millimeter/hour (mm/hr). A higher rate is consistent with inflammation.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · mm/hr
Change in Erythrocyte Sedimentation Rate (ESR) From Baseline at Week 12 and Week 24
mm/hrPlaceboINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Baseline40.8 ± 15.4042.8 ± 17.6237.3 ± 21.5634.8 ± 29.05
Change from baseline at Week 12-6.1 ± 15.76-7.5 ± 23.17-10.7 ± 21.52-5.9 ± 32.35
Change from baseline at Week 24NA ± NA-11.5 ± 21.96-12.8 ± 20.74-11.1 ± 26.00
SecondaryChange in C-reactive Protein (CRP) From Baseline at Week 12 and Week 24

The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · mg/L
Change in C-reactive Protein (CRP) From Baseline at Week 12 and Week 24
mg/LPlaceboINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Baseline10.89 ± 11.55615.63 ± 17.32715.64 ± 16.1137.52 ± 8.581
Change from baseline at Week 120.18 ± 10.063-9.76 ± 16.053-4.01 ± 26.799-0.73 ± 13.488
Change from baseline at Week 24NA ± NA-6.74 ± 18.086-7.90 ± 16.713-5.52 ± 9.017
SecondaryChange in Duration of Morning Stiffness From Baseline at Week 12 and Week 24

Duration of morning stiffness was defined as the time elapsed when participant woke up in the morning and was able to resume normal activities without stiffness in minutes (If none was present = 0; If morning stiffness was continuing at the time of assessment or was unusual compared to the recent past, average of duration of stiffness over the past 3 days was reported; If stiffness persisted the entire day, 1440 minutes was recorded).

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · Minutes
Change in Duration of Morning Stiffness From Baseline at Week 12 and Week 24
MinutesPlaceboINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Baseline78.5 ± 61.36179.8 ± 347.48125.5 ± 246.7579.2 ± 56.83
Change from baseline at Week 122.6 ± 69.23-51.1 ± 94.80-92.6 ± 250.51-42.2 ± 63.97
Change from baseline at Week 24NA ± NA-120.6 ± 245.35-99.3 ± 254.05-51.5 ± 70.84
SecondaryPercentage of Participants Achieving Good European League Against Rheumatism (EULAR) Response (DAS28 ESR) at Week 12

EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Good European League Against Rheumatism (EULAR) Response (DAS28 ESR) at Week 12
percentage of participantsPlaceboINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Percentage of Participants Achieving Good European League Against Rheumatism (EULAR) Response (DAS28 ESR) at Week 1219.023.031.013.0
SecondaryPercentage of Participants Achieving Good EULAR Response (DAS28ESR) at Week 24

EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Good EULAR Response (DAS28ESR) at Week 24
percentage of participantsPlacebo to INCB028050 7 mg QDPlacebo to INCB028050 10 mg QDINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Percentage of Participants Achieving Good EULAR Response (DAS28ESR) at Week 2421.015.033.043.039.0
SecondaryPercentage of Participants Achieving Good EULAR Response (DAS28CRP) at Week 12

EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 2.6.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Good EULAR Response (DAS28CRP) at Week 12
percentage of participantsPlaceboINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Percentage of Participants Achieving Good EULAR Response (DAS28CRP) at Week 1226.039.034.033.0
SecondaryPercentage of Participants Achieving Good EULAR Response (DAS28CRP) at Week 24

EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 2.6.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Good EULAR Response (DAS28CRP) at Week 24
percentage of participantsINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Percentage of Participants Achieving Good EULAR Response (DAS28CRP) at Week 2448.053.065.0
SecondaryChange in SF-36 Mental Component Summary From Baseline at Week 12 and Week 24

The Health Assessment Questionnaire Short Form 36 (SF-36) determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Scales 5-8 primarily contribute to the mental component summary score (PCS) of the SF-36. Scores on each scale are summed and averaged (range = 0 "worst"-100 "best").

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · scores on a scale
Change in SF-36 Mental Component Summary From Baseline at Week 12 and Week 24
scores on a scalePlaceboINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Baseline71.08 ± 27.53469.03 ± 28.18178.41 ± 30.32978.62 ± 24.160
Change from baseline at Week 122.92 ± 19.6137.87 ± 19.5472.21 ± 17.8146.36 ± 25.203
Change from baseline at Week 24NA ± NA7.72 ± 17.5434.60 ± 17.1462.29 ± 28.869
SecondaryChange in SF-36 Physical Component Summary From Baseline at Week 12 and Week 24

The Health Assessment Questionnaire Short Form 36 (SF-36) determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Scales 1-4 primarily contribute to the physical component summary score (PCS) of the SF-36. Scores on each scale are summed and averaged (range = 0 "worst"-100 "best").

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · scores on a scale
Change in SF-36 Physical Component Summary From Baseline at Week 12 and Week 24
scores on a scalePlaceboINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Baseline29.14 ± 14.33034.67 ± 16.00626.71 ± 14.64228.82 ± 14.212
Change from baseline at Week 123.72 ± 11.0279.57 ± 14.96012.97 ± 17.9328.35 ± 13.947
Change from baseline at Week 24NA ± NA11.60 ± 14.50315.56 ± 16.14411.77 ± 13.387
SecondaryPercent of Participants Achieving a Minimum Clinically Important Difference (MCID) in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 and Week 24

HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. The MCID score for HAQ-DI is -0.22.

Time frame:
Week 12 and Week 24
Reported as:
Number · percentage of participants
Percent of Participants Achieving a Minimum Clinically Important Difference (MCID) in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 and Week 24
percentage of participantsPlaceboINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Week 12 (n=31, 31, 30, 30)45.061.063.043.0
Week 24NA67.075.060.0
SecondaryPercent of Participants Achieving a MCID in the Pain Score (Participant's Assessment of Pain) at Week 12 and Week 24

Participants were to assess their current level of pain on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no pain" and the right-hand (100 mm) as "most imaginable pain". MCID for the pain score is a decrease of at least 10 mm on a 100 mm scale.

Time frame:
Week 12 and Week 24
Reported as:
Number · percentage of participants
Percent of Participants Achieving a MCID in the Pain Score (Participant's Assessment of Pain) at Week 12 and Week 24
percentage of participantsPlaceboINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Week 1235.058.069.067.0
Week 24NA59.070.072.0
SecondaryPercent of Participants Achieving a MCID in the SF-36 Physical Components and Mental Components at Week 12 and Week 24

The Health Assessment Questionnaire Short Form 36 (SF-36) determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Scales 5-8 primarily contribute to the mental component summary score (PCS) of the SF-36. Scores on each scale are summed and averaged (range = 0 "worst"-100 "best").

Time frame:
Week 12 and Week 24
Reported as:
Number · percentage of participants
Percent of Participants Achieving a MCID in the SF-36 Physical Components and Mental Components at Week 12 and Week 24
percentage of participantsPlaceboINCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QD
Week 12 Physical Components52.068.069.057.0
Week 24 Physical ComponentsNA67.077.076.0
Week 12 Mental Components52.058.041.050.0
Week 24 Mental ComponentsNA63.057.052.0

Adverse events

Collected over Screening through follow-up visit up to approximately 8 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Weeks 0-12)—0/31 (0%)23/31 (74.2%)
INCB028050 4 mg QD (Weeks 0-12)—0/31 (0%)19/31 (61.3%)
INCB028050 7 mg QD (Weeks 0-12)—1/32 (3.1%)15/32 (46.9%)
INCB028050 10 mg QD (Weeks 0-12)—0/31 (0%)20/31 (64.5%)
Placebo to INCB028050 7 mg QD—0/14 (0%)11/14 (78.6%)
Placebo to INCB028050 10 mg QD—0/15 (0%)9/15 (60%)
INCB028050 4 mg QD (Weeks 12-24)—0/29 (0%)11/29 (37.9%)
INCB028050 7 mg QD (Weeks 12-24)—1/30 (3.3%)17/30 (56.7%)
INCB028050 10 mg QD (Weeks 12-24)—0/27 (0%)6/27 (22.2%)
Placebo to INCB028050 7 mg QD (After Week 24 to Week 28)—0/14 (0%)0/14 (0%)
Placebo to INCB028050 10 mg QD (After Week 24 to Week 28)—1/15 (6.7%)1/15 (6.7%)
INCB028050 4 mg QD (After Week 24 to Week 28)—0/29 (0%)3/29 (10.3%)
INCB028050 7 mg QD (After Week 24 to Week 28)—0/30 (0%)5/30 (16.7%)
INCB028050 10 mg QD (After Week 24 to Week 28)—0/27 (0%)2/27 (7.4%)
Most frequent serious events
Most frequent serious events
EventPlacebo (Weeks 0-12)INCB028050 4 mg QD (Weeks 0-12)INCB028050 7 mg QD (Weeks 0-12)INCB028050 10 mg QD (Weeks 0-12)Placebo to INCB028050 7 mg QDPlacebo to INCB028050 10 mg QDINCB028050 4 mg QD (Weeks 12-24)INCB028050 7 mg QD (Weeks 12-24)INCB028050 10 mg QD (Weeks 12-24)Placebo to INCB028050 7 mg QD (After Week 24 to Week 28)Placebo to INCB028050 10 mg QD (After Week 24 to Week 28)INCB028050 4 mg QD (After Week 24 to Week 28)INCB028050 7 mg QD (After Week 24 to Week 28)INCB028050 10 mg QD (After Week 24 to Week 28)
Cerebrovascular accidentNervous system disorders0/310/310/320/310/140/150/290/300/270/141/150/290/300/27
Mallory-Weiss syndromeGastrointestinal disorders0/310/310/320/310/140/150/291/300/270/140/150/290/300/27
Erosive oesophagitisGastrointestinal disorders0/310/311/320/310/140/150/290/300/270/140/150/290/300/27
ThrombophlebitisVascular disorders0/310/311/320/310/140/150/290/300/270/140/150/290/300/27
Most frequent other events
Showing 10 of 37
Most frequent other events
EventPlacebo (Weeks 0-12)INCB028050 4 mg QD (Weeks 0-12)INCB028050 7 mg QD (Weeks 0-12)INCB028050 10 mg QD (Weeks 0-12)Placebo to INCB028050 7 mg QDPlacebo to INCB028050 10 mg QDINCB028050 4 mg QD (Weeks 12-24)INCB028050 7 mg QD (Weeks 12-24)INCB028050 10 mg QD (Weeks 12-24)Placebo to INCB028050 7 mg QD (After Week 24 to Week 28)Placebo to INCB028050 10 mg QD (After Week 24 to Week 28)INCB028050 4 mg QD (After Week 24 to Week 28)INCB028050 7 mg QD (After Week 24 to Week 28)INCB028050 10 mg QD (After Week 24 to Week 28)
BronchitisInfections and infestations1/311/312/321/312/140/150/290/300/270/140/150/290/300/27
PyrexiaGeneral disorders0/310/310/320/311/142/150/290/300/270/140/150/290/300/27
HeadacheNervous system disorders2/314/313/323/310/141/151/291/300/270/140/150/290/300/27
AnemiaBlood and lymphatic system disorders0/310/310/320/310/140/150/291/303/270/140/150/290/300/27
Herpes zosterInfections and infestations0/310/310/320/310/140/150/293/300/270/140/150/290/300/27
Upper respiratory tract infectionInfections and infestations3/312/312/321/310/140/150/290/300/270/140/150/290/300/27
SinusitisInfections and infestations2/311/313/321/311/140/150/291/300/270/140/150/290/300/27
CoughRespiratory, thoracic and mediastinal disorders1/310/313/321/310/141/151/292/300/270/140/150/290/300/27
VomitingGastrointestinal disorders0/310/310/320/311/140/150/292/302/270/140/150/290/300/27
InfluenzaInfections and infestations1/310/310/322/311/140/150/291/300/270/140/150/290/300/27

Baseline characteristics

Age, Continuous
Age, Continuous(years)INCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QDPlaceboTotal
Mean56.8 ± 12.2853.7 ± 10.9257.3 ± 10.3855.2 ± 10.0955.8 ± 10.92
Sex: Female, Male
Sex: Female, Male(Participants)INCB028050 4 mg QDINCB028050 7 mg QDINCB028050 10 mg QDPlaceboTotal
Female29262522102
Male367925
08

Study locations

49 sites
  • Birmingham, Alabama, United States
  • Paradise Valley, Arizona, United States
  • Peoria, Arizona, United States
  • Phoenix, Arizona, United States
  • Palm Desert, California, United States
  • Santa Maria, California, United States
  • Santa Monica, California, United States
  • Westlake Village, California, United States
  • Whittier, California, United States
  • Denver, Colorado, United States
  • Aventura, Florida, United States
  • Daytona Beach, Florida, United States
  • Gainesville, Florida, United States
  • Lake Mary, Florida, United States
  • Naples, Florida, United States
  • Palm Harbor, Florida, United States
  • Sarasota, Florida, United States
  • Springfield, Illinois, United States
  • South Bend, Indiana, United States
  • Wichita, Kansas, United States
  • Lexington, Kentucky, United States
  • Frederick, Maryland, United States
  • Wheaton, Maryland, United States
  • Saint Louis, Missouri, United States
  • Lincoln, Nebraska, United States
  • Reno, Nevada, United States
  • Freehold, New Jersey, United States
  • Lake Success, New York, United States
  • Syracuse, New York, United States
  • Charlotte, North Carolina, United States
  • Hickory, North Carolina, United States
  • Middleburg Heights, Ohio, United States
  • Toledo, Ohio, United States
  • Tulsa, Oklahoma, United States
  • Duncansville, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Sellersville, Pennsylvania, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Arlington, Virginia, United States
  • Spokane, Washington, United States
  • Brno, Czechia
  • Ceska Lipa, Czechia
  • Chomutov, Czechia
  • Hlucin, Czechia
  • Hustopece, Czechia
  • Kromeriz, Czechia
  • Praha, Czechia
  • Zlin, Czechia
09

References and documents

Publications

  • Taylor PC, Takeuchi T, Burmester GR, Durez P, Smolen JS, Deberdt W, Issa M, Terres JR, Bello N, Winthrop KL. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. 2022 Mar;81(3):335-343. doi: 10.1136/annrheumdis-2021-221276. Epub 2021 Oct 27. PubMed 34706874 ↗
  • Combe B, Balsa A, Sarzi-Puttini P, Tony HP, de la Torre I, Rogai V, Durand F, Witt S, Zhong J, Dougados M. Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib. Ann Rheum Dis. 2019 Aug;78(8):1135-1138. doi: 10.1136/annrheumdis-2018-214261. Epub 2019 Mar 6. No abstract available. PubMed 30842122 ↗
  • Taylor PC, Kremer JM, Emery P, Zuckerman SH, Ruotolo G, Zhong J, Chen L, Witt S, Saifan C, Kurzawa M, Otvos JD, Connelly MA, Macias WL, Schlichting DE, Rooney TP, de Bono S, McInnes IB. Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. Ann Rheum Dis. 2018 Jul;77(7):988-995. doi: 10.1136/annrheumdis-2017-212461. Epub 2018 Feb 20. PubMed 29463520 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Jun 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2018, 8 years 3 months after primary completion. A results delay was requested in Jun 2010.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2009
First posted
May 15, 2009
Start
May 2009
Primary completionActual
Jun 2010
CompletionActual
Jul 2010
Results delay requested
Jun 18, 2010
Results first posted
Sep 4, 2018
Last update
Sep 4, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00902486
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
May 15, 2009
Start date
May 2009
Primary completion
Jun 2010
Completion
Jul 2010
Results posted
Sep 4, 2018
Last update
Sep 4, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion